...
首页> 外文期刊>Surgical neurology >Gliomas: advances in molecular analysis and characterization.
【24h】

Gliomas: advances in molecular analysis and characterization.

机译:神经胶质瘤:分子分析和表征方面的进展。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Gliomas represent the most common primary brain tumor. Despite recent advances in diagnostic imaging, neurosurgical technique, radiation therapy, and chemotherapy, significant advances in accurate prognosis and improved survival have not been achieved. Nevertheless, new developments in molecular biology could have potential impact on the clinical management of patients with these brain tumors. This review will describe the technological advances being used to enrich the classification of gliomas, present specific studies that have successfully used the new technologies to identify molecular subtypes of glioblastoma, and discuss the implications of such enhanced classification and molecular characterizations for the prediction of therapeutic response and the design of future brain tumor therapies. RESULTS: Innovative techniques using complementary DNA and oligonucleotide microarrays (gene chips), tissue microarrays (tissue chips), and differential immunoabsorption have provided high throughput and potentially comprehensive approaches for the molecular characterization of human gliomas. Alterations of several tumor suppressor genes and oncogenes have already been identified as being critical to glioma transformation and progression. These approaches have led to the subclassification of glioblastoma multiforme into distinct subtypes based on the molecular signatures of the tumors. CONCLUSIONS: Classifications of gliomas can now be enhanced with new techniques for comprehensive molecular characterization. Improved and efficient molecular profiling of brain tumors is advancing diagnosis/prognosis and identifying targets for novel and rational therapeutic approaches. Neurosurgeons and neuro-oncologists should be aware of these new developments so they can better advise and treat their patients.
机译:背景:神经胶质瘤是最常见的原发性脑肿瘤。尽管在诊断成像,神经外科技术,放射疗法和化学疗法方面取得了最新进展,但在准确的预后和改善的生存率方面还没有取得重大进展。然而,分子生物学的新发展可能会对这些脑肿瘤患者的临床治疗产生潜在影响。这篇综述将描述用于丰富神经胶质瘤分类的技术进步,介绍已成功使用新技术鉴定胶质母细胞瘤分子亚型的具体研究,并讨论这种增强的分类和分子表征对治疗反应预测的意义。以及未来脑肿瘤疗法的设计。结果:使用互补DNA和寡核苷酸微阵列(基因芯片),组织微阵列(组织芯片)和差异免疫吸收的创新技术为人类神经胶质瘤的分子表征提供了高通量和潜在的综合方法。已经发现几种肿瘤抑制基因和癌基因的改变对神经胶质瘤的转化和进展至关重要。这些方法已经导致多形性胶质母细胞瘤根据肿瘤的分子特征而分为不同的亚型。结论:胶质瘤的分类现在可以通过新技术进行全面的分子鉴定。改善和有效的脑肿瘤分子图谱正在推进诊断/预后并确定新颖合理的治疗方法的靶标。神经外科医生和神经肿瘤学家应该意识到这些新发展,以便他们可以更好地为患者提供建议和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号